Company Deep Dive
Business segments breakdown, earnings transcript analysis, management credibility scoring, competitive landscape, and scenario modelling.
NPCE
SELLNeuroPace, Inc. · Healthcare · United States · $505M · Avg Vol: $3M/d
COMPANY DESCRIPTION
NeuroPace, Inc. is a medical device company focused on developing and commercializing its RNS System, an FDA-approved brain-responsive neurostimulation system for treating focal epilepsy that is not controlled by medication. The company holds a unique position with its personalized, closed-loop technology that monitors and responds to brain activity to prevent seizures. NeuroPace benefits from significant intellectual property and a specialized market within neurology, addressing a critical unmet need for patients.
FINANCIAL SUMMARY (USD)
| Year | 2021 | 2022 | 2023 | 2024 | 2025 | CAGR | TTM | 2026E | 2027E | Fwd CAGR |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | — | 45.5M | 65.4M | 79.9M | 100.0M | 30.0% | 99.5M | 99.9M | 123.4M | 11.1% |
| EPS | -2.17 | -1.91 | -1.27 | -0.93 | -0.66 | — | -0.64 | -0.54 | -0.29 | — |
| Shares | — | 25.0M | 27.8M | 30.1M | 33.6M | +34.1% | 34.1M | — | — | — |
| Debt | — | 69.8M | 72.4M | 73.3M | 70.8M | 0.5% | 70.5M | — | — | — |
| Equity | — | 34.8M | 20.7M | 8.0M | 19.0M | -18.2% | — | — | — | — |
| Op CF | — | -36.9M | -19.7M | -17.9M | -11.0M | — | -9.4M | — | — | — |
| Inv CF | — | 23.8M | 23.0M | 9.0M | -0.3M | — | — | — | — | — |
| Fin CF | — | 0.5M | 8.1M | 4.3M | 19.6M | — | — | — | — | — |
SCORE BREAKDOWN
FUNDAMENTALS
SECTOR PEERS
Closest peers in Healthcare, ranked by industry match, size, and score similarity. Cross-listings of NPCE are excluded.
| Ticker | Company | Mkt Cap | StockRank | Signal |
|---|---|---|---|---|
| NPCE | NeuroPace, Inc.(you) | $505M | 32 | SELL |
| CTKB | Cytek Biosciences, Inc. | $576M | 40 | HOLD |
| TMCI | Treace Medical Concepts, Inc. | $259M | 33 | SELL |
| CBLL | CeriBell, Inc. | $642M | 22 | SELL |
| CERS | Cerus Corporation | $587M | 46 | HOLD |
| SIBN | SI-BONE, Inc. | $737M | 42 | HOLD |
| BBNX | Beta Bionics, Inc. | $706M | 21 | SELL |
| IMR.AX | Imricor Medical Systems, Inc. | $455M | 16 | STRONG SELL |
| KIDS | OrthoPediatrics Corp. | $485M | 50 | HOLD |
| LAB | Standard BioTools Inc. | $326M | 22 | SELL |
Peer medians: ROE -25.5% · P/E 27.7x · Gross margin 50.5%